Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Apply
Afatinib
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step